For a 64-year-old male with type 1 diabetes, weighing 82 kg, remote history of failed pancreas transplant and recent free flap reconstruction, who is on insulin glargine (Lantus) 14 U daily and uses an insulin‑to‑carbohydrate ratio of 1 U per 11 g, what should his inpatient Lantus dose be?

Inpatient Lantus Dosing for Type 1 Diabetes

Reduce the Lantus dose to approximately 7-10 units daily (50-70% of home dose) upon hospital admission, and implement a full basal-bolus regimen with scheduled rapid-acting insulin before meals plus correction doses.

Rationale for Dose Reduction

This patient is clearly "overbasalized" at home—using 14 units of Lantus but rarely taking mealtime insulin despite a 1:11 carb ratio. The Endocrine Society guidelines for hospitalized patients explicitly recommend against simply continuing home insulin regimens unchanged 1. For a patient with type 1 diabetes weighing 82 kg who is hospitalized:

• Calculate total daily dose (TDD): For type 1 diabetes in the hospital, start with 0.2-0.3 U/kg for patients at higher risk of hypoglycemia (which includes post-surgical patients like this one with recent free flap reconstruction) 1
• This patient's calculation: 82 kg × 0.2-0.3 = 16-25 units TDD
• Split 50/50: Approximately 8-12 units as basal (Lantus), with the remainder as prandial insulin 1

Specific Dosing Algorithm

Starting regimen:

• Lantus: 8-10 units once daily (approximately 50% reduction from home dose)
• Rapid-acting insulin: 3-4 units before each meal (if eating)
• Correction insulin: Use the "insulin-sensitive" column from the Endocrine Society protocol given recent surgery and risk factors 1:
  • BG 141-180 mg/dL: add 2 units
  • BG 181-220 mg/dL: add 4 units
  • BG 221-260 mg/dL: add 6 units
  • Continue per protocol table

Critical Safety Considerations

Why reduce the basal dose:

1. Hospitalized patients eat less reliably than at home—meals may be delayed, interrupted, or refused
2. This patient rarely uses mealtime insulin at home, meaning his basal insulin is compensating for meals (classic overbasalization)
3. Post-surgical state increases hypoglycemia risk 1, 2
4. Type 1 diabetes requires basal insulin at all times to prevent DKA, but the dose must be appropriate for the clinical context 1, 3

Common pitfall to avoid: Do NOT discontinue basal insulin entirely, even if the patient is NPO. Patients with type 1 diabetes require continuous basal insulin to prevent ketoacidosis 1, 3. If NPO, give the reduced basal dose (7-10 units) and provide correction insulin every 4-6 hours with rapid-acting analog 1.

Monitoring and Titration

• Check blood glucose before meals and at bedtime (minimum 4 times daily)
• Adjust basal insulin based on fasting and overnight glucose patterns
• Adjust prandial insulin based on pre-meal and 2-hour post-meal glucose
• If hypoglycemia occurs (<70 mg/dL), reduce the corresponding insulin component by 10-20% 1, 4
• Increase doses by 2 units every 1-2 days if glucose remains elevated without hypoglycemia 1

Special Considerations for This Patient

Given the remote history of failed pancreas transplant, this patient has pure type 1 diabetes with no endogenous insulin production 5, 6. The recent ENT free flap surgery likely means:

• Altered oral intake patterns
• Possible NPO periods
• Stress hyperglycemia from surgery/inflammation
• Need for more frequent glucose monitoring

If patient becomes NPO: Maintain basal insulin at 7-10 units, start D5 or D10 containing IV fluids, and give correction doses of rapid-acting insulin every 4 hours 1, 7, 3.

The basal-bolus approach with reduced initial dosing provides the safest transition to inpatient management while maintaining glycemic control and minimizing hypoglycemia risk in this vulnerable post-surgical period 1, 2.